Ciantra Z, Paraskevopoulou V, Aifantis I
Nat Immunol. 2025; 26(3):351-365.
PMID: 40021898
DOI: 10.1038/s41590-025-02096-9.
Danielson D, Aguilera N, Auerbach A
Head Neck Pathol. 2025; 19(1):10.
PMID: 39873807
PMC: 11775375.
DOI: 10.1007/s12105-025-01751-9.
Liu J, An Y, Sun R, Zhang X, Guo S, Gao X
Front Oncol. 2025; 14():1478888.
PMID: 39845313
PMC: 11752923.
DOI: 10.3389/fonc.2024.1478888.
Calvo J, Naguibneva I, Kypraios A, Gilain F, Uzan B, Gaillard B
Leukemia. 2024; 39(2):323-336.
PMID: 39580584
PMC: 11794132.
DOI: 10.1038/s41375-024-02473-7.
Hayakawa F, Mori N, Imai K, Yokoyama Y, Katsuoka Y, Saito T
Cancer Sci. 2024; 116(2):453-461.
PMID: 39572007
PMC: 11786320.
DOI: 10.1111/cas.16405.
Cells and signals of the leukemic microenvironment that support progression of T-cell acute lymphoblastic leukemia (T-ALL).
Lyu A, Nam S, Humphrey R, Horton T, Ehrlich L
Exp Mol Med. 2024; 56(11):2337-2347.
PMID: 39482533
PMC: 11612169.
DOI: 10.1038/s12276-024-01335-7.
[Prognostic factors in children with acute T-lymphoblastic leukemia: a single-center clinical study of the CCCG-ALL-2015 protocol].
Fu W, Fang Y
Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(10):1078-1085.
PMID: 39467678
PMC: 11527409.
DOI: 10.7499/j.issn.1008-8830.2402079.
From Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies.
Golla U, Patel S, Shah N, Talamo S, Bhalodia R, Claxton D
Cancers (Basel). 2024; 16(20).
PMID: 39456548
PMC: 11506385.
DOI: 10.3390/cancers16203454.
Molecular significance of circRNAs in malignant lymphoproliferative disorders: pathogenesis and novel biomarkers or therapeutic targets.
Long B, Wang Y, Hao S, Shi G
Am J Cancer Res. 2024; 14(9):4633-4651.
PMID: 39417189
PMC: 11477815.
DOI: 10.62347/KMWB5164.
[Ruxolitinib combined with venetoclax and azacitidine in the treatment of refractory T-ALL patients with JAK1, JAK3, and STAT5B gene mutations: a case report and literature review].
Xu P, Zhou T, Xu Y, Peng M, Du Y, Xie T
Zhonghua Xue Ye Xue Za Zhi. 2024; 45(9):872-875.
PMID: 39414615
PMC: 11518909.
DOI: 10.3760/cma.j.cn121090-20240412-00138.
Cannabinoid combination targets -mutated T-cell acute lymphoblastic leukemia through the integrated stress response pathway.
Besser E, Gelfand A, Procaccia S, Berman P, Meiri D
Elife. 2024; 12.
PMID: 39258755
PMC: 11390110.
DOI: 10.7554/eLife.90854.
QRICH1 suppresses pediatric T-cell acute lymphoblastic leukemia by inhibiting GRP78.
Zhao J, Kang M, Li H, Rong L, Wang Y, Xue Y
Cell Death Dis. 2024; 15(9):646.
PMID: 39227586
PMC: 11371816.
DOI: 10.1038/s41419-024-07040-7.
Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control.
Lin H, Cheng J, Zhu L, Zeng Y, Dai Z, Zhang Y
Blood Cancer J. 2024; 14(1):98.
PMID: 38890292
PMC: 11189405.
DOI: 10.1038/s41408-024-01082-y.
Acute lymphoblastic leukaemia.
Pagliaro L, Chen S, Herranz D, Mecucci C, Harrison C, Mullighan C
Nat Rev Dis Primers. 2024; 10(1):41.
PMID: 38871740
DOI: 10.1038/s41572-024-00525-x.
Dihydroartemisinin induces ferroptosis in T cell acute lymphoblastic leukemia cells by downregulating SLC7A11 and activating the ATF4‑CHOP signaling pathway.
Tang N, Liu X, Liu Y, Wang H, Zhao Y, Wang H
Oncol Lett. 2024; 28(1):337.
PMID: 38846431
PMC: 11153983.
DOI: 10.3892/ol.2024.14470.
Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study.
Shen Y, Liu M, Shen D, Chu M, Li X, Zhang X
Bone Marrow Transplant. 2024; 59(7):1037-1039.
PMID: 38615141
DOI: 10.1038/s41409-024-02280-9.
Thymic-Epithelial-Cell-Dependent Microenvironment Influences Proliferation and Apoptosis of Leukemic Cells.
Patel S, Zhdanovskaya N, Sergio I, Cardinale A, Rosichini M, Varricchio C
Int J Mol Sci. 2024; 25(3).
PMID: 38338689
PMC: 10855934.
DOI: 10.3390/ijms25031412.
An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL).
Wang S, Zhang R, Zhong K, Guo W, Tong A
Biomolecules. 2024; 14(1).
PMID: 38254706
PMC: 10813019.
DOI: 10.3390/biom14010106.
Development of PD-1 blockade peptide-cell conjugates to enhance cellular therapies for T-cell acute lymphoblastic leukemia.
Wang Q, Huang H, Liang P, Wang L, Zheng J, Zhang Y
Med Oncol. 2023; 41(1):14.
PMID: 38078948
DOI: 10.1007/s12032-023-02235-y.
Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe.
Din R, Jiao A, Qiu Y, Mohan A, Yuen K, Wong H
Int J Mol Sci. 2023; 24(19).
PMID: 37834095
PMC: 10572992.
DOI: 10.3390/ijms241914646.